Health effects of utilising hospital contacts to provide measles vaccination to children 9-59 months-a randomised controlled trial in Guinea-Bissau

Ane B Fisker, Justiniano S D Martins, Andreas M Jensen, Cesario Martins, Peter Aaby, Sanne M Thysen, Ane B Fisker, Justiniano S D Martins, Andreas M Jensen, Cesario Martins, Peter Aaby, Sanne M Thysen

Abstract

Background: Measles vaccination coverage in Guinea-Bissau is low; fewer than 80% of children are currently measles vaccinated before 12 months of age. The low coverage hampers control of measles. Furthermore, accumulating evidence indicates that measles vaccine has beneficial non-specific effects, strengthening the resistance towards other infections. Thus, even if children are not exposed to measles virus, measles-unvaccinated children may be worse off. To increase vaccination coverage, WHO recommends that contacts with the health system for mild illness are utilised to vaccinate. Currently, in Guinea-Bissau, curative health system contacts are not utilised.

Methods: Bandim Health Project registers out-patient consultations and admissions at the paediatric ward of the National Hospital in Guinea-Bissau. Measles-unvaccinated children aged 9-59 months consulting for milder illness or being discharged from the paediatric ward will be invited to participate in a randomised trial. Among 5400 children, randomised 1:1 to receive standard measles vaccine or a saline placebo, we will test the hypothesis that providing a measles vaccine at discharge lowers the risk of admission/mortality (composite outcome) during the subsequent 6 months by 25%. All enrolled children are followed through the Bandim Health Project registration system and through telephone follow-up. The first 1000 enrolled children are furthermore followed through interviews on days 2, 4, 7 and 14 after enrolment.

Discussion: Utilising missed vaccination opportunities can increase vaccination coverage and may improve child health. However, without further evidence for the safety and potential benefits of measles vaccination, these curative contacts are unlikely to be used for vaccination in Guinea-Bissau.

Trial registration: www.

Clinicaltrials: gov NCT04220671 . Registered on 5 January 2020.

Keywords: Hospital admission; Measles vaccine; Mortality; Non-specific (heterologous) effects of vaccines.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Vaccination schedule in Guinea-Bissau

References

    1. World Health Organization. Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec. 2017;92(17):205-27.
    1. Hanson CM, Mirza I, Kumapley R, Ogbuanu I, Kezaala R, Nandy R. Enhancing immunization during second year of life by reducing missed opportunities for vaccinations in 46 countries. Vaccine. 2018;36(23):3260–3268. doi: 10.1016/j.vaccine.2018.04.070.
    1. Peck M, Gacic-Dobo M, Diallo MS, Nedelec Y, Sodha S, Wallacea AS. Global routine vaccination coverage, 2018. Wkly Epidemiol Rec. 2019;94(43):498–503. doi: 10.15585/mmwr.mm6842a1.
    1. Galazka AM, Lauer BA, Henderson RH, Keja J. Indications and contraindications for vaccines used in the Expanded Programme on Immunization. Bull World Health Organ. 1984;62(3):357–366.
    1. World Health Organisation. Missed Opportunities for Vaccination (MOV) Strategy 2018 Available from: . Accessed 19 Apr 2022.
    1. Ndikuyeze A, Munoz A, Stewart J, Modlin J, Heymann D, Herrmann KL, et al. Immunogenicity and safety of measles vaccine in ill African children. Int J Epidemiol. 1988;17(2):448–455. doi: 10.1093/ije/17.2.448.
    1. Wagstaff LA. A preliminary report on measles and the use of attenuated live measles vaccine in Bantu paediatric hospital practice. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1969;43(21):664–669.
    1. Glyn-Jones R. Measles vaccine gamma globulin in the prevention of cross infection with measles in an acute paediatric ward. Cent Afr J Med. 1972;18(1):4–9.
    1. Harris MF. The safety of measles vaccine in severe illness. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1979;55(2):38.
    1. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J Infect. 1984;8(1):13–21. doi: 10.1016/S0163-4453(84)93192-X.
    1. Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 1995;311(7003):481–485. doi: 10.1136/bmj.311.7003.481.
    1. Aaby P, Bhuiya A, Nahar L, Knudsen K, de Francisco A, Strong M. The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh. Int J Epidemiol. 2003;32(1):106–116. doi: 10.1093/ije/dyg005.
    1. Benn CS, Fisker AB, Rieckmann A, Sorup S, Aaby P. Vaccinology: time to change the paradigm? Lancet Infect Dis. 2020;20(10):e274–ee83. doi: 10.1016/S1473-3099(19)30742-X.
    1. Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170. doi: 10.1136/bmj.i5170.
    1. Aaby P, Garly ML, Bale C, Martins C, Jensen H, Lisse I, et al. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. Pediatr Infect Dis J. 2003;22(9):798–805. doi: 10.1097/01.inf.0000083821.33187.b5.
    1. Aaby P, Martins CL, Garly ML, Bale C, Andersen A, Rodrigues A, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ. 2010;341:c6495. doi: 10.1136/bmj.c6495.
    1. Aaby P, Ravn H, Benn CS, Rodrigues A, Samb B, Ibrahim SA, Libman MD, Whittle HC. Randomized Trials Comparing Inactivated Vaccine After Medium- or High-titer Measles Vaccine With Standard Titer Measles Vaccine After Inactivated Vaccine: A Meta-analysis. Pediatr Infect Dis J. 2016;35(11):1232–1241. doi: 10.1097/INF.0000000000001300.
    1. Fisker AB, Nebie E, Schoeps A, Martins C, Rodrigues A, Zakane A, Kagone M, Byberg S, Thysen SM, Tiendrebeogo J, Coulibaly B, Sankoh O, Becher H, Whittle HC, van der Klis FRM, Benn CS, Sie A, Müller O, Aaby P. A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine: Effects on Mortality and Measles Antibody Levels. Clin Infect Dis. 2018;66(10):1573–1580. doi: 10.1093/cid/cix1033.
    1. Fisker AB, Thysen SM. Non-live pentavalent vaccines after live measles vaccine may increase mortality. Vaccine. 2018;36(41):6039–6042. doi: 10.1016/j.vaccine.2018.08.083.
    1. Aaby P, Andersen A, Martins CL, Fisker AB, Rodrigues A, Whittle HC, Benn CS. Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine. BMJ Open. 2016;6(12):e013335. doi: 10.1136/bmjopen-2016-013335.
    1. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 -- conclusions and recommendations. Wkly Epidemiol Rec. 2014;89(21):221-36.
    1. Sodemann M, Biai S, Jakobsen MS, Aaby P. Knowing a medical doctor is associated with reduced mortality among sick children consulting a paediatric ward in Guinea-Bissau, West Africa. TropMed Int Health. 2006;11(12):1868–1877. doi: 10.1111/j.1365-3156.2006.01744.x.
    1. Andersen A, Bjerregaard-Andersen M, Rodrigues A, Umbasse P, Fisker AB. Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. Vaccine. 2017;35(50):7018–7025. doi: 10.1016/j.vaccine.2017.10.047.
    1. World Health Organisation Verbal autopsy standards: ascertaining and attributing causes of death 2021 [Available from]: . Accessed 3 Oct 2021.
    1. Thysen SM, Fisker AB, Byberg S, Aaby P, Roy P, White R, et al. Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0-4 years. BMJ Glob Health. 2021;6(8):e006127. doi: 10.1136/bmjgh-2021-006127.
    1. Brond M, Martins CL, Byberg S, Benn CS, Whittle H, Garly ML, et al. Randomized Trial of 2 Versus 1 Dose of Measles Vaccine: Effect on Hospital Admission of Children After 9 Months of Age. J Pediatric Infect Dis Soc. 2018;7(3):226–233. doi: 10.1093/jpids/pix042.
    1. Martins CL, Benn CS, Andersen A, Bale C, Schaltz-Buchholzer F, Do VA, et al. A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis. 2014;209(11):1731–1738. doi: 10.1093/infdis/jit804.
    1. Byberg S, Aaby P, Rodrigues A, Benn CS, Fisker AB. The mortality effects of disregarding the strategy to save doses of measles vaccine – a cluster-randomized trial in Guinea-Bissau. BMJ Glob Health. 2021;6:e004328. doi: 10.1136/bmjgh-2020-004328.
    1. Aaby P, Martins C, Bale C, Lisse I. Assessing measles vaccination coverage by maternal recall in Guinea-Bissau. Lancet. 1998;352(9135):1229. doi: 10.1016/S0140-6736(05)60575-2.
    1. Fisker AB, Hornshoj L, Rodrigues A, Balde I, Fernandes M, Benn CS, et al. Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study. Lancet Glob Health. 2014;2(8):e478–e487. doi: 10.1016/S2214-109X(14)70274-8.
    1. Biai S, Rodrigues A, Nielsen J, Sodemann M, Aaby P. Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country. Vaccine. 2011;29(20):3662–3669. doi: 10.1016/j.vaccine.2011.03.016.
    1. Byberg S, Benn CS. Placebo use in vaccine trials: Caution when using active vaccines as placebo. Vaccine. 2017;35(9):1211. doi: 10.1016/j.vaccine.2015.03.024.
    1. World Health Organisation . Planning and Implementing High-Quality Supplementary Immunization Activities for Injectable Vaccines Using an Example of Measles and Rubella Vaccines. 2016.
    1. Byberg S, Fisker AB, Thysen SM, Rodrigues A, Enemark U, Aaby P, Benn CS, Griffiths UK. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau. Glob Health Action. 2017;10(1):1329968. doi: 10.1080/16549716.2017.1329968.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa